相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma
F. Dimitriou et al.
ANNALS OF ONCOLOGY (2022)
The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Michael S. Oh et al.
CLINICAL LUNG CANCER (2021)
Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes
Eliot R. Dow et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2021)
The potential for immune checkpoint modulators in cerebrovascular injury and inflammation
Jennifer E. Kim et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2021)
Spectrum and impact of checkpoint inhibitor-induced irAEs
Laura C. Cappelli et al.
NATURE REVIEWS RHEUMATOLOGY (2021)
A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitors-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention
Spencer C. Wei et al.
CANCER DISCOVERY (2021)
Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma
Taigo Kato et al.
ONCOIMMUNOLOGY (2021)
Outcomes of Patients With Interstitial Lung Disease Receiving Programmed Cell Death 1 Inhibitors: A Retrospective Case Series
Ioana A. Dobre et al.
CLINICAL LUNG CANCER (2021)
The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients
S. Street et al.
ANNALS OF ONCOLOGY (2021)
Delayed immune-related adverse events with an PD-1-based immunotherapy in melanoma
C. N. Owen et al.
ANNALS OF ONCOLOGY (2021)
Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity
L. L. Thompson et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy
Selina K. Wong et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
Briana Rose Halle et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment
Christopher A. Muir et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
Daniel J. Olson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Immune Checkpoint Inhibitor-related Guillain-Barre Syndrome: A Case Series and Review of the Literature
Jorien B. E. Janssen et al.
JOURNAL OF IMMUNOTHERAPY (2021)
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2021)
The changing landscape of atherosclerosis
Peter Libby
NATURE (2021)
CD4+ T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice
Yoshinori Yasuda et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma
J. Randall Patrinely et al.
JAMA ONCOLOGY (2021)
Obesity results in adipose tissue T cell exhaustion
Cara E. Porsche et al.
JCI INSIGHT (2021)
Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study
M. Guida et al.
ESMO OPEN (2021)
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy
Xue Bai et al.
CLINICAL CANCER RESEARCH (2021)
Original Research Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
Helen Dearden et al.
EUROPEAN JOURNAL OF CANCER (2021)
Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study
Martin Salzmann et al.
EUROPEAN JOURNAL OF CANCER (2021)
Metabolic disease and adverse events from immune checkpoint inhibitors
Amanda Leiter et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2021)
Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Miles C. Andrews et al.
NATURE MEDICINE (2021)
Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry
Michel M. Sun et al.
OPHTHALMOLOGY (2021)
Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer
Ajeeth K. Pingili et al.
CELL REPORTS (2021)
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Amanda C. Guidon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R. Brahmer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy
Jichang Han et al.
NATURE CANCER (2021)
Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors
Sarah Waliany et al.
JACC: CARDIOONCOLOGY (2021)
A multicenter characterization of hepatitis associated with immune checkpoint inhibitors
J. Randall Patrinely et al.
ONCOIMMUNOLOGY (2021)
Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment
Christopher A. Muir et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
THYROID DYSFUNCTION, RECOVERY, AND PROGNOSIS IN MELANOMA PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A RETROSPECTIVE REVIEW
Mazen Al Mushref et al.
ENDOCRINE PRACTICE (2020)
CD8+ T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease
Denitra A. Breuer et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2020)
Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors
Laura X. Wang et al.
CANCER (2020)
The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma
Daniel Y. Wang et al.
ONCOLOGIST (2020)
Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma
Ivelina Spassova et al.
CLINICAL CANCER RESEARCH (2020)
Neurologic complications of immune checkpoint inhibitors
Alexandra M. Haugh et al.
EXPERT OPINION ON DRUG SAFETY (2020)
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
Ahmad A. Tarhini et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
Allison Betof Warner et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
Hamzah Abu-Sbeih et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study
Frank B. Cortazar et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Management of Immunotherapy-Related Toxicities, Version 1.2020 Featured Updates to the NCCN Guidelines
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature
Vivek Kumar et al.
ONCOLOGIST (2020)
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo A Secondary Analysis of a Randomized Clinical Trial
Alexander M. M. Eggermont et al.
JAMA ONCOLOGY (2020)
Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α
Liku B. Tezera et al.
ELIFE (2020)
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
Alessio Cortellini et al.
EUROPEAN JOURNAL OF CANCER (2020)
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis
Eleftheria Chorti et al.
EUROPEAN JOURNAL OF CANCER (2020)
Early T cell infiltration is modulated by programed cell death-1 protein and its ligand (PD-1/PD-L1) interactions in murine kidney transplants
Young Jun Shim et al.
KIDNEY INTERNATIONAL (2020)
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
Charles Dolladille et al.
JAMA ONCOLOGY (2020)
COVID-19 and immune checkpoint inhibitors: initial considerations
Ryan J. Sullivan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis
Virginie Grouthier et al.
ONCOLOGIST (2020)
Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors
Ohad Oren et al.
AMERICAN JOURNAL OF CARDIOLOGY (2020)
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
J. Haanen et al.
ANNALS OF ONCOLOGY (2020)
Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort
Janet Roberts et al.
AUTOIMMUNITY REVIEWS (2020)
Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities
Yves Allenbach et al.
AUTOIMMUNITY REVIEWS (2020)
Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand
James Randall Patrinely et al.
EUROPEAN JOURNAL OF CANCER (2020)
Diagnostic and therapeutic differences between immune checkpoint inhibitor-induced and idiopathic bullous pemphigoid: a cross-sectional study
G. E. Molina et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
Adrienne M. Luoma et al.
CELL (2020)
Association of Impaired Spermatogenesis With the Use of Immune Checkpoint Inhibitors in Patients With Metastatic Melanoma
Jason M. Scovell et al.
JAMA ONCOLOGY (2020)
Immune checkpoint inhibitor-associated celiac disease
Yousef Badran et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Impact of body composition on outcomes from anti-PD1+/- anti-CTLA-4 treatment in melanoma
Arissa C. Young et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis
Michael Li et al.
CANCER (2020)
Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque
Zsofia D. Drobni et al.
CIRCULATION (2020)
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153
David M. Waterhouse et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
Alexander M. M. Eggermont et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2020)
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Reinhard Dummer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
Laurence Albiges et al.
ESMO OPEN (2020)
Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy An Expert Consensus Document
Enrico Ammirati et al.
CIRCULATION-HEART FAILURE (2020)
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
Bin Zhao et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Immune checkpoint inhibitor-induced inflammatory arthritis: a qualitative study identifying unmet patient needs and care gaps
Laura C. Cappelli et al.
BMC RHEUMATOLOGY (2020)
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Chipman R. G. Stroud et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Y. J. L. Jansen et al.
ANNALS OF ONCOLOGY (2019)
A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Jeroen de Filette et al.
HORMONE AND METABOLIC RESEARCH (2019)
Hematologic Complications of Immune Checkpoint Inhibitors
Elizabeth J. Davis et al.
ONCOLOGIST (2019)
PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model
Neta Rosenzweig et al.
NATURE COMMUNICATIONS (2019)
Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review
Hiroko Kadota et al.
CURRENT RHEUMATOLOGY REPORTS (2019)
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Alessio Cortellini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity.
Daniel H. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy
Blake M. Warner et al.
ONCOLOGIST (2019)
The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders
Chanjuan Ma et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Fiamma Berner et al.
JAMA ONCOLOGY (2019)
Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma
Henry T. Quach et al.
JAMA ONCOLOGY (2019)
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Douglas B. Johnson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Myocarditis in the Setting of Cancer Therapeutics Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology
Marc P. Bonaca et al.
CIRCULATION (2019)
Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes
Venessa H. M. Tsang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
Hamzah Abu-Sbeih et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Gregory S. Phillips et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis
Douglas B. Johnson et al.
NATURE MEDICINE (2019)
Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy
Khashayar Esfahani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis
Joe-Elie Salem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab
Suzanne L. Topalian et al.
JAMA ONCOLOGY (2019)
Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis
Alexander Faje et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)
Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies
Divyanshu Dubey et al.
NEUROLOGY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients
Douglas B. Johnson et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events
Yousef R. Badran et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations
Amalia Anastasopoulou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Single-cell immune landscape of human atherosclerotic plaques
Dawn M. Fernandez et al.
NATURE MEDICINE (2019)
Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management
Chandra K. Ala et al.
CURRENT CARDIOLOGY REPORTS (2019)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature
Kerry L. Reynolds et al.
ONCOLOGIST (2019)
Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database
Julie Garon-Czmil et al.
SCIENTIFIC REPORTS (2019)
Defining 'T cell exhaustion'
Christian U. Blank et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 28, pg 119, 2017)
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2018)
High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
Alexander T. Faje et al.
CANCER (2018)
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Angeliki Stamatouli et al.
DIABETES (2018)
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
Rituparna Das et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
Caroline Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed S. Mahmood et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Javid J. Moslehi et al.
LANCET (2018)
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
Jennifer L. McQuade et al.
LANCET ONCOLOGY (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen
Laura C. Cappelli et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
Fernando C. Santini et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
Priyanka C. Iyer et al.
THYROID (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes
Jordan J. Wright et al.
DIABETES CARE (2018)
Immune Checkpoint Inhibitor Toxicity in 2018
Douglas B. Johnson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
Joe-Elie Salem et al.
LANCET ONCOLOGY (2018)
Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case-Control Study
Yael Eshet et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma
R. J. Lee et al.
ANNALS OF ONCOLOGY (2018)
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
Douglas B. Johnson et al.
JCI INSIGHT (2018)
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
M. H. Pollack et al.
ANNALS OF ONCOLOGY (2018)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A. M. Menzies et al.
ANNALS OF ONCOLOGY (2017)
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
Laura C. Cappelli et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Pregnancy promotes tolerance to future offspring by programming selective dysfunction in long-lived maternal T cells
Brendan M. Barton et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2017)
Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients
Valentine Heidelberger et al.
INVESTIGATIONAL NEW DRUGS (2017)
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Chromatin states define tumour-specific T cell dysfunction and reprogramming
Mary Philip et al.
NATURE (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
Jarushka Naidoo et al.
ONCOLOGIST (2017)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman et al.
NATURE COMMUNICATIONS (2017)
Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
Hyunju Lee et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
Eileen Shiuan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Smoldering myocarditis following immune checkpoint blockade
Timothy G. Norwood et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment
Rakiba Belkhir et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Combinatorial approach to cancer immunotherapy: strength in numbers
Anna E. Vilgelm et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2016)
PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease
Kuti Baruch et al.
NATURE MEDICINE (2016)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cardiovascular Toxic Effects of Targeted Cancer Therapies
Javid J. Moslehi
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Krista Dubin et al.
NATURE COMMUNICATIONS (2016)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson et al.
JAMA ONCOLOGY (2016)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma
Douglas B. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation
Sheetal Bodhankar et al.
STROKE (2015)
Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center
Douglas B. Johnson et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
Shintaro Iwama et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Opportunistic infections in patients treated with immunotherapy for cancer
Chrisann Kyi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
The Cardiovascular Perils of Cancer Survivorship
Javid Moslehi
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives
Steven M. Bair et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Programmed Death-1 Pathway Limits Central Nervous System Inflammation and Neurologic Deficits in Murine Experimental Stroke
Xuefang Ren et al.
STROKE (2011)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation.
Ted A. Gooley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group
Jean-Pierre Pignon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell-mediated injury in the heart
Nir Grabie et al.
CIRCULATION (2007)
Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice
Israel Gotsman et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
One thousand consecutive pancreaticoduodenectomies
JL Cameron et al.
ANNALS OF SURGERY (2006)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)